And platinum medicine is officially listed on the Hong Kong Stock Exchange today

According to the HKEx IPO announcement, and Platinum Pharmaceuticals was officially listed on the main board of the Hong Kong Stock Exchange on December 10.
and Platinum Pharmaceuticals filed an IPO application under Chapter 18A of the HKEx Listing Rules in August this year, which was heard by HKEx in November.
co-sponsors of the hong Kong-based listing under the prospectus and Platinum Pharmaceuticals are Morgan Stanley, BofA Securities and Citic Lyons .CLSA.
announcement, the company's shares were issued at HK$12.38 per share, resulting in a net proceeds of about HK$1,598.8 million.
Screenshot Source: And Platinum Pharmaceuticals Prospectus and Platinum Pharmaceuticals were established in 2016 as an innovative biopharmaceutical company dedicated to the development of next-generation immunological and oncology immunotherapy, founded by Dr. Wang Jinsong.
hong Kong Stock Exchange IPO, cornerstone investors include BlackRock Fund, HBM Healthcare, Anlan Fund, Union Capital, Obo Capital Fund and so on.
, and Platinum Pharmaceuticals has established an exclusive antibody platform equipped with a full range of highly efficient antibody discovery and technology to improve or amplification antibody efficacy, including an extension of HCAb platform as an important technology and HBICETM platform.
the same time, the company has successfully established a highly differentiated and rich pipeline of innovative products through a diversified partnership model such as independent innovation research and development and the introduction of strategic projects, and four products have entered the clinical stage. the net proceeds from the IPO of
and Platinum Pharmaceuticals in Research Products (Photo Source: References) are expected to be used as follows: approximately 37% of the net proceeds from the IPO are as follows: approximately 37% of the funds raised by Platinum Pharmaceuticals are used for core assets Bartoli monoanti (HBM9) 161) and Tnasip (HBM9036) ongoing and planned clinical trials and other related research and development activities in Greater China, preparation for registration and potential commercial launch; 03 Ongoing and planned clinical trials in Greater China and Australia, preparation for registration and potential commercial roll-out in Greater China, the United States and other jurisdictions; Research and development, including HBM9302, HBM1007, HBM7008, etc.; Use and platinum antibody platforms to seek licensing and cooperation opportunities; About 8% will be used for working capital and other general corporate purposes.
4 products have entered the clinical stage. FcRn inhibitor Bartoli monoant: a product introduced by And Platinum Pharmaceuticals that enjoys the development and commercialization interests of Greater China.
this product can be used to bind and inhibit specific neonatal Fc subjects (FcRn) to accelerate the removal of IgG antibodies in the body, thereby effectively treating pathogenic IgG-mediated autoimmune diseases.
it has demonstrated its best-in-class potential in existing studies and is being developed as a simpler and more convenient treatment for intraderses.
The product was the first to select four adaptations for primary immunocompromise platelet reduction (ITP), thyroid-related eye disease (GO), severe muscle weakness (MG), and optic neurospinal cord disease (NMOSD), some of which have entered the registered clinical stage.
, according to the prospectus, Bartoli monoantigen has the potential to become a breakthrough therapy for many types of autoimmune diseases in Greater China.
mechanism for the single-resistance mechanism (Screenshot Source: Supplied) TNF-α inhibitor Ternasip: a product introduced by Platinum Pharmaceuticals and which enjoys the development and commercialization interests of Greater China.
is an innovative TNF subject 1 fragment for patients with moderate to severe dry eye disease.
Recently, the product was published in clinical Phase 2 studies for patients with moderate to severe dry eye disease in China, which showed that Tenasip was effective quickly, showed significant improvement in signs measured by corneal chromosomal scores, and had excellent tolerance and similar comfort to a placebo.
this provides strong support for Thenassip to conduct Phase 3 clinical registration trials in China.
Tenasip mechanism of action (Screenshot Source: References.
it is reported that the immune stimulation effect of this product is driven by two mechanisms: 1) inhibits the negative signal produced by the interaction between CTLA-4 and the synergistic stimulation molecule B7;
the product has been conducted in Australia for phase 1 clinical trials of advanced solid tumors and has been approved by IND in the United States.
september of this year, the clinical trial of HBM4003 monopharmaceutical therapy and the anti-PD-1 antibody Ripley monoantigen therapy was approved in China.
mechanism of action of HBM4003 (Screenshot Source: References. HER2/CD3 dual-specific antibody HBM9302: and Platinum Pharmaceuticals were granted an exclusive license in 2018 to develop a product in Greater China.
It binds to both overexposed HER2 molecules and CD3 molecules expressed on the surface of T cells in solid tumor patients, connecting cytotoxic T cells to HER2-positive cancer cells and playing a cytotoxic effect on tumor cells.
the product showed strong tumor growth inhibition in the anti-curvature bead monoantin model.
, the product is currently being tested by partners in Phase 1 clinical trials in Germany and the United States.
HBM9302 Structural Map (Screenshot Source: Reference: References) Promotes Preclinical Phase Assets into clinical Phase Prospectus shows that and Platinum Pharmaceutical intends to promote existing preclinical phase assets into clinical development, including 1) HBM 7020, a dual-specific antibody for BCMA x CD3 containing HCAb immune cell bridger; 3) HBM7015, a dual-functional fusion protein containing PD-L1-inhibited all-human source IgG1 monoclonal antibodies and soluble extracellulation region conversion growth factor beta-liker II (TGFBR2); BM7008, a dual-specific antibody for TAA x 4-1BB, contains HCAb immune cell bridger;
, HBM9022 is particularly noteworthy.
This is an all-human source-based and antibody 47D11 found using a platinum antibody platform that has the potential to prevent and/or treat COVID-19 and has the potential to prevent and/or treat other future emerging human diseases caused by the sabervirus sub-virus.
HBM9022 demonstrated promising properties in the late preclinical stage, acting in a way that blocks the potential of SARS-CoV-2 and SARS-CoV infection.
the product is currently being developed in cooperation with Platinum Pharmaceuticals and AbbVie.
In accordance with the prospectus, after the listing of the Hong Kong stock market, and Platinum Pharma's recent product development strategy is: rapidly advancing the clinical program to seek regulatory approval and its later clinical assets Bartoli monoantitor and Ternasip's commercialization work in China; M4003, HBM7020, HBM7008, etc.;
。